MarketCap
Facebook
X
TelegramQuarterly report 2023-Q1
added 05-15-2023
Lannett Company Operating Income 2011-2025 | LCI
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Lannett Company
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -176 M | -237 M | 19.6 M | -262 M | 130 M | 86.4 M | 131 M | 226 M | 88.1 M | 18.8 M | 6.91 M | -1.18 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 226 M | -262 M | 2.47 M |
Quarterly Operating Income Lannett Company
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -86.7 M | -14.8 M | -13 M | -27.8 M | -22.1 M | -68.1 M | -8.15 M | -76.2 M | 2.85 M | -217 M | -15 K | -217 M | -15 K | 16.8 M | 9.4 M | 16.8 M | 9.4 M | 36.7 M | -342 M | 36.7 M | -342 M | 47.1 M | 40.7 M | 47.1 M | 40.7 M | 34.3 M | -20.3 M | 34.3 M | -20.3 M | 30.3 M | 51.4 M | 30.3 M | 51.4 M | 66.5 M | 54.7 M | 66.5 M | 54.7 M | 25.4 M | -10.6 M | 25.4 M | -10.6 M | 4.69 M | 3.69 M | 4.69 M | 3.69 M | 495 K | 1.44 M | 495 K | 1.45 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 66.5 M | -342 M | -13.2 M |
Operating Income of other stocks in the Drug manufacturers industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
-1.93 M | - | - | $ 142 M |  USA |
 |
Canopy Growth Corporation
CGC
|
-117 M | $ 1.31 | -6.43 % | $ 141 M |  Canada |
 |
Aerie Pharmaceuticals
AERI
|
-46.4 M | - | - | $ 754 M | USA |
 |
AcelRx Pharmaceuticals
ACRX
|
-15.3 M | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-25.1 M | - | 0.86 % | $ 117 M | USA |
 |
Agile Therapeutics
AGRX
|
-19.9 M | - | 10.11 % | $ 58.2 M | USA |
 |
Catalent
CTLT
|
-749 M | - | - | $ 11.5 B | USA |
 |
Aurora Cannabis
ACB
|
-283 M | $ 4.57 | -1.72 % | $ 86.3 M | Canada |
 |
DURECT Corporation
DRRX
|
-36.9 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
81 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
-469 M | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
-7.43 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-524 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-85.5 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Emergent BioSolutions
EBS
|
-726 M | $ 12.63 | 0.72 % | $ 647 M | USA |
 |
Organogenesis Holdings
ORGO
|
-1.28 M | $ 5.87 | 2.09 % | $ 773 M | USA |
 |
Pacira BioSciences
PCRX
|
-73.4 M | $ 26.02 | 1.09 % | $ 1.2 B | USA |
 |
Athenex
ATNX
|
-70 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-42.4 M | $ 21.58 | 0.19 % | $ 2.05 B |  France |
 |
Rockwell Medical
RMTI
|
-6.67 M | $ 0.81 | -0.81 % | $ 18.9 M | USA |
 |
Solid Biosciences
SLDB
|
-130 M | $ 5.9 | - | $ 241 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-3.71 M | $ 3.64 | 1.68 % | $ 4.52 M | USA |
 |
Evolus
EOLS
|
-34.4 M | $ 6.85 | 0.59 % | $ 425 M | USA |
 |
Harrow Health
HROW
|
431 K | $ 50.16 | 2.05 % | $ 1.64 B | USA |
 |
OrganiGram Holdings
OGI
|
-91.8 M | $ 1.76 | 1.15 % | $ 402 M | Canada |
 |
China Pharma Holdings
CPHI
|
-4.59 M | $ 1.31 | -1.5 % | $ 22.9 M |  China |
 |
Bausch Health Companies
BHC
|
963 M | $ 7.18 | -1.91 % | $ 2.62 B | Canada |
 |
Neoleukin Therapeutics
NLTX
|
-55.6 M | - | - | $ 193 M | Canada |
 |
Veru
VERU
|
-36.9 M | $ 2.34 | 0.86 % | $ 316 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
-1.84 M | $ 4.2 | -1.41 % | $ 59.1 M | USA |
 |
cbdMD
YCBD
|
-3.32 M | $ 1.59 | -4.22 % | $ 6.86 M | USA |
 |
PetIQ
PETQ
|
37.1 M | - | 1.64 % | $ 400 M | USA |
 |
Radius Health
RDUS
|
-54.3 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
-3.57 M | - | -4.76 % | $ 65.3 M | USA |
 |
Perrigo Company plc
PRGO
|
113 M | $ 13.75 | 0.47 % | $ 1.89 B | USA |
 |
ProPhase Labs
PRPH
|
23.6 M | $ 0.62 | -10.48 % | $ 9.82 M | USA |
 |
Relmada Therapeutics
RLMD
|
-104 M | $ 4.6 | 2.45 % | $ 138 M | USA |
 |
Sundial Growers
SNDL
|
-132 M | $ 1.77 | -0.56 % | $ 3.37 M | Canada |
 |
OptiNose
OPTN
|
-22.7 M | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
-244 M | $ 0.66 | -0.02 % | $ 46.9 M | USA |
 |
PLx Pharma
PLXP
|
-40.8 M | - | -27.8 % | $ 2.56 M | USA |
 |
SCYNEXIS
SCYX
|
72.7 M | $ 0.6 | 1.78 % | $ 28.7 M | USA |
 |
Tricida
TCDA
|
-153 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
-1.37 B | $ 10.15 | -3.61 % | $ 6.27 B | Canada |
 |
TherapeuticsMD
TXMD
|
-8.52 M | $ 1.7 | 3.66 % | $ 17.7 M | USA |
 |
Viatris
VTRS
|
1.61 B | $ 12.24 | 1.83 % | $ 14.8 B | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-35.3 M | - | - | $ 55.5 M | USA |